Clinical trials: Anticoagulant
Non-valvular Atrial Fibrillation
Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation
This is a prospective, single-center, randomized, exploratory clinical observation to explore the overall benefit of short-term dual antiplatelet or novel oral anticoagulant regimens after left atrial appendage (LAA) occlusion by…
- Trial name
- NCT05761704
- Testing
- Dual antiplatelet, Novel oral anticoagulant
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hemorrhage, Thrombosis
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department
Rationale: According to the latest National Survey on Care-Related Adverse Events, anticoagulants, including vitamin K antagonists (VKAs), rank first among medications responsible for serious iatrogenic accidents (37% in 2004…
- Conditions
- Hemorrhage, Thrombosis, Anticoagulant Therapy, Traumatic Hemorrhage
- Trial name
- ADEOA (NCT06692504)
- Where
- France
- Volunteers
- 2,080 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Atrial Fibrillation
Treatment Pattern of Oral Anticoagulants (OAC) in Japan
1. To understand the treatment patterns of OACs and baseline patient characteristics of Japanese Non-Valvular Atrial Fibrillation (NVAF) patients 2.
- Trial name
- NCT02982863
- Where
- Japan
- Volunteers
- 48,696 people
- Sponsor
- Boehringer Ingelheim
Non-valvular Atrial Fibrillation (NVAF), Thromboembolism
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device, Perioperative Bleeding
- Trial name
- STEP-AF (NCT07616414)
- Testing
- Stepwise Anticoagulation Regimen, Standard Anticoagulation Regimen
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Heparin-Induced Thrombocytopenia, Thrombosis
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome…
- Trial name
- NCT00043940
- Testing
- bivalirudin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Medicines Company
Antithrombinemia
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially…
- Trial name
- EPPATHUS (NCT07276074)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Strasbourg, France
Thromboembolism, Bleeding
Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin
The optimal medical strategy for prevention of thromboembolic events after bioprosthetic aorta valve replacement (BAVR) remains controversial.
- Trial name
- NCT01452568
- Testing
- Aspirin, Warfarin
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Infection, Heart Failure
Home Hospital for Suddenly Ill Adults
The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be…
- Conditions
- Infection, Heart Failure, COPD, Asthma
- Trial name
- NCT03524222
- Testing
- Home Hospitalization
- Where
- 2 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation, Atrial Flutter
Prague Registry of Electric Cardioversion
This single-center observational registry follows contemporary efficacy and short-term complications of elective electric cardioversion.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Atrial Arrhythmia, Atrial Tachycardia
- Trial name
- PRAGUE-ECV (NCT04919902)
- Testing
- Electric cardioversion
- Where
- Czechia
- Volunteers
- 5,000 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Anticoagulants and Bleeding Disorders
MAC Project, Monitoring of AntiCoagulant Therapies (MAC)
MAC Project is a prospective cohort, multicenter, observational, no-profit study aimed to prospectively collect reliable real-life clinical information in unselected VTE or NVAF patients treated with any DOAC, during a…
- Trial name
- MAC (NCT04329390)
- Testing
- Anticoagulant drugs
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Quovadis Associazione
Direct Oral Anticoagulants (DOACs), Oral Surgical Procedures
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited.
- Trial name
- DOACS_BX (NCT07520890)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Venous Thromboembolism
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04735523
- Testing
- Dabigatran, Warfarin
- Where
- United States
- Volunteers
- 5,350 people
- Sponsor
- Brigham and Women's Hospital
COVID-19, Deep Vein Thrombosis
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
To see whether our increased dosing regimen of unfractionated heparin (UF) and low molecular weight heparin (LMWH) in COVID-19 patients was effective at preventing thrombo-embolic complications.
- Conditions
- COVID-19, Deep Vein Thrombosis, Anticoagulants and Bleeding Disorders, Critical Illness
- Trial name
- NCT05224388
- Testing
- Enoxaparin, Heparin
- Where
- Belgium
- Volunteers
- 813 people
- Sponsor
- University Hospital, Ghent
Healthy Volunteers
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
Background: Rivaroxaban and apixaban are blood thinners. People with HIV may need to take them to treat or prevent blood clots. The anti-HIV drug darunavir (DRV) can increase the amount of these blood thinners in the body.
- Trial name
- NCT03864406
- Testing
- Cobicistat, Darunavir/Cobicistat, Rivaroxaban
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Renal Insufficiency
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic…
- Trial name
- VERDICT (NCT02664155)
- Testing
- Apixaban, Rivaroxaban, Heparin
- Where
- 31 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hemorrhage
Evaluation of the Impact of an Expert Opinion During the Management of Patients With Severe Bleeding on Oral Anticoagulants.
The goal of this randomized clinical trial is to evaluate the impact of an expert opinion during the management of patients with severe bleeding on oral anticoagulants.
- Trial name
- BANET (NCT05928091)
- Testing
- Phone call to an expert team
- Where
- 15 sites in France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Clermont-Ferrand
Atrial Fibrillation, Non-valvular Atrial Fibrillation
Therapy With New Oral Anticoagulants
The aim of the present registry is to characterize and follow patients prospectively and retrospectively with renal impairment who have been prescribed apixaban for the prevention of stroke in atrial fibrillation, with a…
- Trial name
- NCT02222090
- Where
- Israel
- Volunteers
- 1,500 people
- Sponsor
- Sheba Medical Center
Hematoma
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery.
- Trial name
- BRUISECONTROL2 (NCT01675076)
- Testing
- Dabigatran, Rivaroxaban, Apixaban
- Where
- 15 sites in Canada, Israel
- Volunteers
- 663 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cancer, Atrial Fibrillation
Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy
- Trial name
- MAFIC (NCT04508855)
- Testing
- Low molecular weight heparin
- Where
- 2 sites in Greece
- Sponsor
- AHEPA University Hospital